USDAR Registry

Study Info

Started In 2017

Sites 12

Enrolled 2,697

USDAR Registry: Premise

Millions of people in the United States report a drug allergy on their medical record, often many drug allergies. However, studies have shown that most people with a reported drug allergy can safely tolerate that drug through testing. Allergies can fade over time, and drug allergies are often misidentified, both adding to the overreporting of drug allergies. Unfortunately, current research lacks enough data to identify strong patterns among people with drug allergies and their chances of positive allergy testing, especially what happens after allergy testing long-term. To start addressing this gap in research, the US Drug Allergy Registry was founded as the first prospective drug allergy registry study. Through USDAR, people across the country who decide to test their drug allergies can contribute their experience and results to help improve drug allergy knowledge and care.

Allergy confirmed or allergy disproved

Piecing together connections between medical histories and testing results may allow for highly accurate models to predict or prevent drug allergies.

Benefits to health care

Following people’s use of health care after their drug allergy testing lets researchers measure the benefits of drug allergy testing and develop ways to make test results more impactful.

Building a community of patients and clinicians

Clinical research relies on a close and cooperative relationship between patients and clinicians. USDAR aims to bring people together impacted by drug allergy, to gather information and advance care.